This study aimed to investigate the serum levels of inflammatory markers in adolescents with major depressive disorder (MDD) using selective serotonin reuptake inhibitors.
Methods:
This was an 8-month observational study, involving 30 adolescents with and 38 without (control) MDD diagnosis. Demographic (age and gender) and anthropometric data (weight, height, and calculated body mass index [BMI] z score) were collected. Body composition was assessed with whole-body DXA scan. Depressive and anxiety symptoms were assessed using the Beck Depression and Anxiety Inventories (BDI-II and BAI), respectively. Serum levels of interleukin (IL)-6, IL-8, IL-1β, tumor necrosis factor, monocyte chemoattractant protein-1 (MCP-1), leptin, resistin, and adiponectin were measured using Bio-Plex Multiplex Immunoassays at baseline and after 8 months.
Results:
At baseline, patients with MDD and controls did not differ in age, gender, BMI z score, and fat mass index (FMI) z score. At follow-up, 58.3% (21/36) of patients with MDD were in full remission. Patients with MDD had higher levels of resistin at baseline (26274.16 pg/mL [16162.68–54252.72]) than controls (21678.53 pg/mL [11221.17–37343.27]; p < 0.01). This difference remained statistically significant after adjustment for sex, age, and FMI z score. No differences in other inflammatory markers were observed between the groups. By follow up, depressive and anxiety symptom severity had decreased significantly in patients with MDD in parallel with a decrease in the serum levels of TNF (p = 0.02), IL-8 (p < 0.01) and MCP-1 (p = 0.04). Among these markers, BDI-II score was positively correlated with serum levels of MCP-1.
Conclusion:
These results corroborate the view of involvement of peripheral inflammatory mechanisms in the pathophysiology of MDD in adolescents.
This trial is registered at ClinicalTrials.gov: NCT02147184.
Get full access to this article
View all access options for this article.
References
1.
AliyaziciogluR, DeğerO, Vanizor KuralB, Hocaoğlu Ç, ÇolakM, Balaban YücesanF: The relationship between the peroxisome proliferator-activated receptor gamma 2 gene polymorphism, lipids and adipokines in patients with major depression. Turkiye Klinikleri J Med Sci, 31:1065–1072, 2011.
2.
American Psychiatric Association: Diagnostic and Statistical Manual of MentalDisorders, FourthEdition. Washington, DC: American Psychiatric Association; 2000.
3.
AvenevoliS, SwendsenJ, HeJP, BursteinM, MerikangasKR: Major depression in the national comorbidity survey-adolescent supplement: Prevalence, correlates, and treatment. J Am Acad Child Adolesc Psychiatry, 54:37–44.e2, 2015.
4.
BarnesJ, MondelliV, ParianteCM: Genetic contributions of inflammation to depression. Neuropsychopharmacology, 42:81–98, 2017.
5.
BeckAT, EpsteinN, BrownG, SteerRA: An inventory for measuring clinical anxiety: Psychometric properties. J Consult Clin Psychol, 56:893–897, 1988.
6.
BeckAT, WardCH, MendelsonM, MockJ, ErbaughJ: An inventory for measuring depression. Arch Gen Psychiatry, 4:561–571, 1961.
7.
BenomarY, GertlerA, De LacyP, CrepinD, Ould HamoudaH, RiffaultL, TaouisM: Central resistin overexposure induces insulin resistance through Toll-like receptor 4. Diabetes, 62:102–114, 2013.
8.
CalargeCA, ButcherBD, BurnsTL, CoryellWH, SchlechteJA, ZemelBS: Major depressive disorder and bone mass in adolescents and young adults. J Bone Miner Res, 29:2230–2237, 2014.
9.
CalargeCA, MillsJA, JanzKF, BurnsTL, CoryellWH, ZemelBS: Body composition in adolescents during treatment with selective serotonin reuptake inhibitors. Pediatrics, 140:e20163943, 2017.
10.
ColasantoM, MadiganS, KorczakDJ: Depression and inflammation among children and adolescents: A meta-analysis. J Affect Disord, 277:940–948, 2020.
11.
CoryellW, MillsJ, DindoL, CalargeCA: Predictors of depressive symptom trajectories in a prospective follow-up of late adolescents. Psychol Med, 50:2283–2288, 2020.
DeumicE, ButcherBD, ClaytonAD, DindoLN, BurnsTL, CalargeCA: Sexual functioning in adolescents with major depressive disorder. J Clin Psychiatry, 77:957–962, 2016.
14.
DowlatiY, HerrmannN, SwardfagerW, LiuH, ShamL, ReimEK, LanctotKL: A meta-analysis of cytokines in major depression. Biol Psychiatry, 67:446–457, 2010.
15.
DuivisHE, de JongeP, PenninxBW, NaBY, CohenBE, WhooleyMA: Depressive symptoms, health behaviors, and subsequent inflammation in patients with coronary heart disease: Prospective findings from the heart and soul study. Am J Psychiatry, 168:913–920, 2011.
16.
EyreHA, AirT, PradhanA, JohnstonJ, LavretskyH, StuartMJ, BauneBT: A meta-analysis of chemokines in major depression. Prog Neuropsychopharmacol Biol Psychiatry, 68:1–8, 2016.
17.
GardnerMJ, ThomasHJ, ErskineHE: The association between five forms of child maltreatment and depressive and anxiety disorders: A systematic review and meta-analysis. Child Abuse Negl, 96:104082, 2019.
18.
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators: Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet, 392:1789–1858, 2018.
19.
HickieI, CarpenterJS, ScottEM: Adolescent-onset depressive disorders and inflammation. In: Inflammation and Immunity in Depression. Edited by BauneBT. Cambridge, Massachusetts, Academic Press, 2018, pp. 427–443.
20.
HowrenMB, LamkinDM, SulsJ: Associations of depression with C-reactive protein, IL-1, and IL-6: A meta-analysis. Psychosom Med, 71:171–186, 2009.
21.
KesslerRC, BerglundP, DemlerO, JinR, MerikangasKR, WaltersEE: Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry, 62:593–602, 2005.
22.
KimJW, SzigethyEM, MelhemNM, SaghafiEM, BrentDA: Inflammatory markers and the pathogenesis of pediatric depression and suicide: A systematic review of the literature. J Clin Psychiatry, 75:1242–1253, 2014.
23.
Kohler-ForsbergO, LydholmCN, HjorthojC, NordentoftM, MorsO, BenrosME: Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: Meta-analysis of clinical trials. Acta Psychiatr Scand, 139:404–419, 2019.
24.
LehtoSM, HuotariA, NiskanenL, TolmunenT, Koivumaa-HonkanenH, HonkalampiK, RuotsalainenH, HerzigKH, ViinamakiH, HintikkaJ: Serum adiponectin and resistin levels in major depressive disorder. Acta Psychiatr Scand, 121:209–215, 2010.
25.
LeightonSP, NerurkarL, KrishnadasR, JohnmanC, GrahamGJ, CavanaghJ: Chemokines in depression in health and in inflammatory illness: A systematic review and meta-analysis. Mol Psychiatry, 23:48–58, 2018.
MendelsonT, TandonSD: Prevention of depression in childhood and adolescence. Child Adolesc Psychiatr Clin N Am, 25:201–218, 2016.
28.
MillsNT, ScottJG, WrayNR, Cohen-WoodsS, BauneBT: Research review: The role of cytokines in depression in adolescents: A systematic review. J Child Psychol Psychiatry, 54:816–835, 2013.
29.
MisiakB, BartoliF, CarraG, MaleckaM, SamochowiecJ, JaroszK, BanikA, StanczykiewiczB: Chemokine alterations in bipolar disorder: A systematic review and meta-analysis. Brain Behav Immun, 88:870–877, 2020.
30.
MitchellRH, GoldsteinBI: Inflammation in children and adolescents with neuropsychiatric disorders: A systematic review. J Am Acad Child Adolesc Psychiatry, 53:274–296, 2014.
31.
MorrisAA, ZhaoL, AhmedY, StoyanovaN, De StaerckeC, HooperWC, GibbonsG, Din-DziethamR, QuyyumiA, VaccarinoV: Association between depression and inflammation—Differences by race and sex: The META-Health study. Psychosom Med, 73:462–468, 2011.
32.
MoultonCD, PickupJC, IsmailK: The link between depression and diabetes: The search for shared mechanisms. Lancet Diabetes Endocrinol, 3:461–471, 2015.
33.
OgdenCL, KuczmarskiRJ, FlegalKM, MeiZ, GuoS, WeiR, Grummer-StrawnLM, CurtinLR, RocheAF, JohnsonCL: Centers for Disease Control and Prevention 2000 growth charts for the United States: Improvements to the 1977 National Center for Health Statistics version. Pediatrics, 109:45–60, 2002.
34.
PanA, YeX, FrancoOH, LiH, YuZ, WangJ, QiQ, GuW, PangX, LiuH, LinX: The association of depressive symptoms with inflammatory factors and adipokines in middle-aged and older Chinese. PLoS One, 3:e1392, 2008.
35.
PapakostasGI, SheltonRC, KinrysG, HenryME, BakowBR, LipkinSH, PiB, ThurmondL, BilelloJA: Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: A pilot and replication study. Mol Psychiatry, 18:332–339, 2013.
36.
RochaNP, ColpoGD, Bravo-AlegriaJ, LincolnJA, WolinskyJS, LindseyJW, TeixeiraAL, FreemanL: Exploring the relationship between Endothelin-1 and peripheral inflammation in multiple sclerosis. J Neuroimmunol, 326:45–48, 2019.
37.
ShafferD, FisherP, LucasCP, DulcanMK, Schwab-StoneME: NIMH Diagnostic Interview Schedule for Children Version IV (NIMH DISC-IV): description, differences from previous versions, and reliability of some common diagnoses. J Am Acad Child Adolesc Psychiatry, 391:28–38, 2000.
38.
StewartJC, RandKL, MuldoonMF, KamarckTW: A prospective evaluation of the directionality of the depression-inflammation relationship. Brain Behav Immun, 23:936–944, 2009.
39.
StrawbridgeR, ArnoneD, DaneseA, PapadopoulosA, Herane VivesA, CleareAJ: Inflammation and clinical response to treatment in depression: A meta-analysis. Eur Neuropsychopharmacol, 25:1532–1543, 2015.
40.
SuKZ, LiYR, ZhangD, YuanJH, ZhangCS, LiuY, SongLM, LinQ, LiMW, DongJ: Relation of circulating resistin to insulin resistance in type 2 diabetes and obesity: A systematic review and meta-analysis. Front Physiol, 10:1399, 2019.
41.
Veru-LesmesF, GuayS, ShahJL, SchmitzN, GiguereCE, JooberR, IyerSN, MallaAK: Adipose tissue dysregulation at the onset of psychosis: Adipokines and social determinants of health. Psychoneuroendocrinology, 123:104915, 2021.
42.
WeberDR, MooreRH, LeonardMB, ZemelBS: Fat and lean BMI reference curves in children and adolescents and their utility in identifying excess adiposity compared with BMI and percentage body fat. Am J Clin Nutr, 98:49–56, 2013.
43.
Weber-HamannB, KratzschJ, KopfD, LederbogenF, GillesM, HeuserI, DeuschleM: Resistin and adiponectin in major depression: the association with free cortisol and effects of antidepressant treatment. J Psychiatr Res, 41:344–350, 2007.
